AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19563192 — intervention group
Group type: COMPARATOR
Intervention: Selecting points based on differentiation of syndromes group (DS)
Number of subjects: 40
Study 16911626 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine twice daily at breakfast and dinner
Number of subjects: 20
Study 16911626 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine once daily at dinner time
Number of subjects: 20
Study 15464492 — intervention group
Group type: EXPERIMENTAL
Intervention: Group IV (open ends of grafts)
Number of subjects: 40
Study 15464492 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III (distal end occluded)
Number of subjects: 40
Study 15464492 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (heparinized oxygenated blood, not distended)
Number of subjects: 40
Study 15464492 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (heparinized oxygenated blood, distended)
Number of subjects: 40
Study 11531863 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) 2 mg sublingually 5 min before endoscopy
Number of subjects: 186
Study 11531863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 11531863 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN)
Number of subjects: 186
Study 9010943 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl patch (0.16 mg/cm2) applied 60 minutes before anesthesia induction.
Number of subjects: 40
Study 9010943 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch of identical size.
Number of subjects: 40
Study 9010943 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl patch (50-75 micrograms/h).
Number of subjects: 40
Study 9010943 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac (60 mg intramuscularly) administered approximately 20-30 minutes before expected end of surgery.
Number of subjects: 40
Study 9010943 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (1,300 mg) administered between ketorolac doses if pain persisted.
Number of subjects: 40
Study 9010943 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain relief assessed by VAS at rest and with movement.
Number of subjects: 40
Study 9010943 — intervention group
Group type: EXPERIMENTAL
Intervention: Nausea and vomiting reported.
Number of subjects: 40
Study 8510524 — intervention group
Group type: EXPERIMENTAL
Intervention: Barley (90g carbohydrate)
Number of subjects: 10
Study 8510524 — intervention group
Group type: COMPARATOR
Intervention: Rice (90g carbohydrate)
Number of subjects: 10
Study 3319638 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon calcitonin (100 I.U.s.c. every other day for 6 months)
Number of subjects: 36
Study 3319638 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 36
Study 3319638 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon calcitonin
Number of subjects: 36
Study 29722919 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive behavioural therapy (cCBT) program
Number of subjects: 24
Study 27599612 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate-amodiaquine (ASAQ)
Number of subjects: 288
Study 27599612 — intervention group
Group type: COMPARATOR
Intervention: artemether-lumefantrine (AL)
Number of subjects: 288
Study 24952391 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium stents
Number of subjects: 173
Study 24952391 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stents
Number of subjects: 173
Study 23330427 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation
Number of subjects: 39
Study 23330427 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Positive Pressure Ventilation
Number of subjects: 39
Study 23330427 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous Respiration
Number of subjects: 39
Study 21111980 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose furosemide combined with low-dose dopamine (LDFD, furosemide 5 mg/h plus dopamine 5 μg kg(‐1) min(‐1) continuous infusion for 8 hours)
Number of subjects: 60
Study 21111980 — intervention group
Group type: COMPARATOR
Intervention: High-dose furosemide (HDF, 20 mg/h continuous infusion for 8 hours)
Number of subjects: 60
Study 21111980 — intervention group
Group type: COMPARATOR
Intervention: High-dose furosemide (HDF)
Number of subjects: 60
Study 21111980 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose furosemide combined with low-dose dopamine (LDFD)
Number of subjects: 60
Study 19140569 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel and extended-release dipyridamole/low-dose aspirin
Number of subjects: 39742
Study 19140569 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antiplatelet therapy (clopidogrel plus aspirin)
Number of subjects: 39742
Study 19140569 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release dipyridamole/low-dose aspirin
Number of subjects: 39742
Study 19140569 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 39742
Study 16767410 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (8 mg)
Number of subjects: 16
Study 16767410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 14564112 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (AP) treatment lasting 30 min a day, conducted during and after 34 weeks of pregnancy.
Number of subjects: 67
Study 14564112 — intervention group
Group type: COMPARATOR
Intervention: Control group without acupuncture treatment.
Number of subjects: 67
Study 10762510 — intervention group
Group type: EXPERIMENTAL
Intervention: FcgammaRIIa-H131 homozygosity in GBS patients
Number of subjects: 31
Study 10762510 — intervention group
Group type: EXPERIMENTAL
Intervention: FcgammaRIIa-H131 homozygous GBS patients
Number of subjects: 31
Study 10762510 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 31
Study 8816577 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 150-mg oral dose of fluconazole
Number of subjects: 0
Study 8816577 — intervention group
Group type: COMPARATOR
Intervention: Intravaginal antifungal agents
Number of subjects: 0
Study 1384305 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan (5-HTP) 900 mg/d
Number of subjects: 20
Study 1384305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3892151 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial 18-week chemotherapy (vincristine, actinomycin D, cyclophosphamide, adriamycin) followed by local therapy (radical surgery or radiation)
Number of subjects: 83
Study 3892151 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical surgery
Number of subjects: 83
Study 3892151 — intervention group
Group type: COMPARATOR
Intervention: Radiation only (46 gy vs 60 gy)
Number of subjects: 83
Study 3892151 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor volume less than 100 ml
Number of subjects: 83
Study 3892151 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor volume greater than or equal to 100 ml
Number of subjects: 83
Study 28936586 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Patient Education (PTE)
Number of subjects: 600
Study 28936586 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Patient Education (PTE)
Number of subjects: 600
Study 28936586 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 600
Study 27649653 — intervention group
Group type: EXPERIMENTAL
Intervention: FOCUS Harmonic Scalpel
Number of subjects: 361
Study 27649653 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 361
Study 25694375 — intervention group
Group type: EXPERIMENTAL
Intervention: Craniosacral therapy (G-CST)
Number of subjects: 55
Study 25694375 — intervention group
Group type: COMPARATOR
Intervention: Trigger point therapy (G-TPT)
Number of subjects: 55
Study 22450173 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based quality improvement tool
Number of subjects: 37
Study 22450173 — intervention group
Group type: COMPARATOR
Intervention: Control clinics
Number of subjects: 37
Study 20335759 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthopaedic residents
Number of subjects: 139
Study 20335759 — intervention group
Group type: COMPARATOR
Intervention: Nurse practitioners
Number of subjects: 139
Study 18336577 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-stretch bandages (SSBs) applied on one leg according to a standard protocol
Number of subjects: 29
Study 15853230 — intervention group
Group type: EXPERIMENTAL
Intervention: Indisetron hydrochloride
Number of subjects: 0
Study 15853230 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron
Number of subjects: 0
Study 12297477 — intervention group
Group type: EXPERIMENTAL
Intervention: Vit C (300 mg/d) and Vit E (600 mg/d) for 15 days before BMT
Number of subjects: 19
Study 12297477 — intervention group
Group type: COMPARATOR
Intervention: Control group received the same treatment without prior vitamin administration
Number of subjects: 19
Study 12297477 — intervention group
Group type: EXPERIMENTAL
Intervention: Vit C and Vit E supplementation
Number of subjects: 19
Study 12297477 — intervention group
Group type: COMPARATOR
Intervention: Control group without prior vitamin administration
Number of subjects: 19
Study 10429748 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber supplement (20 g/d)
Number of subjects: 169
Study 10429748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 7546582 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic semipermeable absorbent polyurethane foam dressing
Number of subjects: 68
Study 7546582 — intervention group
Group type: COMPARATOR
Intervention: Petrolatum gauze dressing
Number of subjects: 68
Study 2250110 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% minoxidil solution
Number of subjects: 8
Study 2250110 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle only)
Number of subjects: 8
Study 6264641 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglycolic acid
Number of subjects: 210
Study 6264641 — intervention group
Group type: COMPARATOR
Intervention: Nylon
Number of subjects: 210
Study 31602582 — intervention group
Group type: EXPERIMENTAL
Intervention: Mu-suppression in response to painful pictures
Number of subjects: 80
Study 31602582 — intervention group
Group type: EXPERIMENTAL
Intervention: Compassion levels
Number of subjects: 80
Study 31602582 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain ratings
Number of subjects: 80
Study 31602582 — intervention group
Group type: EXPERIMENTAL
Intervention: Mu-suppression and compassion correlation
Number of subjects: 80
Study 30898329 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive text message conversations with Peer Health Educators, plus five daily automated, unidirectional theory-based messages, plus a weekly self-monitoring text message assessment (TXT-PHE; n = 94)
Number of subjects: 286
Study 30898329 — intervention group
Group type: EXPERIMENTAL
Intervention: Five daily automated, unidirectional theory-based messages plus a weekly self-monitoring text message assessment (TXT-Auto; n = 99)
Number of subjects: 286
Study 30898329 — intervention group
Group type: COMPARATOR
Intervention: Weekly self-monitoring text message assessment only (AO; n = 93)
Number of subjects: 286
Study 28212586 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 18
Study 28212586 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 18
Study 25257960 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy ‐ informed psychosis intervention trial
Number of subjects: 7
Study 25257960 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies
Number of subjects: 7
Study 25257960 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative approach
Number of subjects: 7
Study 23792179 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA) - 16 sessions
Number of subjects: 100
Study 23792179 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant Medication (ADM) - unspecified dosage and duration
Number of subjects: 100
Study 23792179 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA)
Number of subjects: 100
Study 23792179 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant Medication (ADM)
Number of subjects: 100
Study 23792179 — intervention group
Group type: COMPARATOR
Intervention: Behavioural Activation (BA) and Antidepressant Medication (ADM)
Number of subjects: 100
Study 20673292 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal pillow (P)
Number of subjects: 21
Study 20673292 — intervention group
Group type: COMPARATOR
Intervention: Standard nasal mask (M)
Number of subjects: 21
Study 19363052 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (PVI)
Number of subjects: 26
Study 19363052 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention mentioned)
Number of subjects: 26
Study 18299686 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide
Number of subjects: 0
Study 18299686 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate
Number of subjects: 0
Study 18299686 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine and mycophenolate
Number of subjects: 0
Study 18299686 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined angiotensin and angiotensin receptor blockade
Number of subjects: 0
Study 18299686 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel treatment options
Number of subjects: 0
Study 15096068 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion sustained release, 150 mg/day, added to cognitive-behavioral therapy for smoking cessation
Number of subjects: 18
Study 15096068 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects who achieved significant smoking reduction during the trial
Number of subjects: 18
Study 15096068 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects who achieved > or = 50% reduction in smoking at the end of the trial
Number of subjects: 18
Study 15096068 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking reduction during the treatment intervention
Number of subjects: 18
Study 11361050 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone acetate foam (100 mg)
Number of subjects: 0
Study 9869251 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitation (impairment-based) approach
Number of subjects: 23
Study 9869251 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-oriented (disability-focused) approach
Number of subjects: 23
Study 7980374 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 3
Study 7980374 — intervention group
Group type: COMPARATOR
Intervention: Behavioral intervention (token economy)
Number of subjects: 3
Study 7980374 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (accuracy targeting)
Number of subjects: 3
Study 3140748 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (single dose 40 mg kg‐1 body weight)
Number of subjects: 0
Study 3140748 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxamniquine (single dose 15 mg kg‐1 body weight)
Number of subjects: 0
Study 3140748 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (split doses)
Number of subjects: 0
Study 3140748 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxamniquine (split doses)
Number of subjects: 0
Study 3140748 — intervention group
Group type: COMPARATOR
Intervention: Praziquantel (single dose)
Number of subjects: 0
Study 3140748 — intervention group
Group type: COMPARATOR
Intervention: Oxamniquine (single dose)
Number of subjects: 0
Study 29185375 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based mindfulness intervention
Number of subjects: 100
Study 29185375 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 100
Study 29659819 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based lifestyle program (6-week duration)
Number of subjects: 16
Study 28612158 — intervention group
Group type: EXPERIMENTAL
Intervention: Early nutritional intervention
Number of subjects: 21
Study 28612158 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 21
Study 28612158 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors affecting survival
Number of subjects: 21
Study 25792830 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel (125 mg/m², days 1, 8, and 15) and carboplatin (AUC=2; days 1, 8, and 15) every 21 days for four cycles
Number of subjects: 120
Study 25792830 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel with trastuzumab
Number of subjects: 120
Study 25792830 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (80 mg/m², days 1, 8, and 15) and carboplatin every 21 days for four cycles
Number of subjects: 120
Study 23517485 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 22
Study 23517485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 21721430 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-items questionnaire
Number of subjects: 20
Study 21721430 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-items clinical score
Number of subjects: 20
Study 18936277 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine femoral nerve blockade
Number of subjects: 56
Study 18936277 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo injection
Number of subjects: 56
Study 16888263 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy intervention
Number of subjects: 118
Study 16888263 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 118
Study 23573600 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting SMART Stents
Number of subjects: 36
Study 23573600 — intervention group
Group type: COMPARATOR
Intervention: Uncoated SMART Stents
Number of subjects: 36
Study 11451552 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacurette
Number of subjects: 200
Study 11451552 — intervention group
Group type: COMPARATOR
Intervention: Pipelle
Number of subjects: 200
Study 9755356 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of selective serotonin reuptake inhibitors with other serotonergic agents
Number of subjects: 0
Study 8091931 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaxigrip vaccine (containing antigens A/Ghizhou/54/89, A/Singapore/6/86, and B/Yamagata/16/88)
Number of subjects: 43
Study 8091931 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaxigrip vaccine
Number of subjects: 43
Study 3291008 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential chemotherapy followed by radiotherapy (Arm A)
Number of subjects: 116
Study 3291008 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating chemotherapy and radiotherapy (Arm B)
Number of subjects: 116
Study 31669003 — intervention group
Group type: EXPERIMENTAL
Intervention: Early high protein intake (1.2–1.5 g/kg/day) in low skeletal muscle area group
Number of subjects: 739
Study 31669003 — intervention group
Group type: EXPERIMENTAL
Intervention: Early high protein intake (1.2–1.5 g/kg/day) in combined low skeletal muscle area and density subgroup
Number of subjects: 739
Study 31669003 — intervention group
Group type: COMPARATOR
Intervention: Normal skeletal muscle area group
Number of subjects: 739
Study 29954333 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making followed by positive reinforcement (SDM&PR)
Number of subjects: 226
Study 29954333 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 226
Study 28193657 — intervention group
Group type: EXPERIMENTAL
Intervention: Velpatasvir (VEL) administered at doses up to 450 mg
Number of subjects: 7
Study 28193657 — intervention group
Group type: EXPERIMENTAL
Intervention: Velpatasvir (VEL) administered with food
Number of subjects: 7
Study 28193657 — intervention group
Group type: EXPERIMENTAL
Intervention: Velpatasvir (VEL) at doses greater than 5 mg
Number of subjects: 7
Study 26085041 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram plus ziprasidone (N=71)
Number of subjects: 139
Study 26085041 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram plus placebo (N=68)
Number of subjects: 139
Study 23597088 — intervention group
Group type: EXPERIMENTAL
Intervention: Case manager guidance within a multidisciplinary setting
Number of subjects: 325
Study 23597088 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention without case manager guidance
Number of subjects: 325
Study 23597088 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model combining baseline clinical and psychosocial risk factors
Number of subjects: 325
Study 22011694 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol 250 mg once daily (QD) after breakfast for 14 days
Number of subjects: 30
Study 22011694 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol 500 mg once daily (QD) after breakfast for 14 days
Number of subjects: 30
Study 22011694 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol 250 mg twice a day (b.i.d) after breakfast and dinner for 14 days
Number of subjects: 30
Study 22011694 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 30
Study 18086182 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried blood spot testing (training and use)
Number of subjects: 28
Study 18086182 — intervention group
Group type: COMPARATOR
Intervention: Control (standard testing)
Number of subjects: 28
Study 14753248 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide HFA 400 microg twice daily
Number of subjects: 298
Study 14753248 — intervention group
Group type: COMPARATOR
Intervention: Budesonide CFC 400 microg twice daily
Number of subjects: 298
Study 14753248 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide HFA 800 microg once daily
Number of subjects: 298
Study 10214654 — intervention group
Group type: EXPERIMENTAL
Intervention: Order 1 (Anxiety Rating Scale‐2 followed by Competitive State Anxiety Inventory‐2)
Number of subjects: 100
Study 10214654 — intervention group
Group type: COMPARATOR
Intervention: Order 2 (Competitive State Anxiety Inventory‐2 followed by Anxiety Rating Scale‐2)
Number of subjects: 100
Study 7542819 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 232
Study 7542819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study 2487696 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest group (n=27 joints)
Number of subjects: 30